According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, geographies across the world are showing insurgent growth in the biotech API Industry. The US occupied more than half of the share in the global market in 2011, and is the largest producer of biotech APIs. Western European countries occupy around 15% share globally among which, the UK is the largest producer of biotechnology-based APIs. The countries in the Asia-Pacific region in particular are likely to witness an improved share in the overall biotech API market, mainly because of significant production of bio-generics. India and China individually will grow at a robust rate of 30-35% backed by several factors, such as availability of cheap resources, infrastructure, labor, raw materials amongst others.
The global biotech API will see growth in its biogeneric API business driven in particular by the loss of patent protection of several blockbuster biotech drugs in near future. The market is also expected to see robust usage and popularity of biosimilars, especially erythropoietin, recombinant human insulin amongst others. At the competitive front, players, such as Bayer Pharma AG, Biocon Limited, Boehringer Ingelheim, Hospira amongst others are leading the biotech API market. These competitors are riding on their core biotech strengths and expanding their biotech API capabilities with active research and innovation activity. RNCOS expects the worldwide API market size to be likely to register a healthy CAGR of around 8% during 2012-2015.
The report spread in over 55 pages provides a proper understanding of the API market globally along with an idea about its current state. The key industry drivers have been covered in details along with the current and future market projections for the time period of 2012-2015. The major segments and sub-segments of the API Industry have been covered along with the description of the API industry in the most promising geographies of India, China, Italy and Taiwan. The report also analyzes the opportunity assessment for companies in the global APIs market in terms of therapeutic segments and countries’ comparative index. An analysis of the emerging areas, competitive landscape, and regulatory stringency further provides a holistic understanding of the global API market.
Some of our Related Reports are:
|
